New treatment option for schizophrenia Reagila(R) listed on PBS

MELBOURNE, Sep 6, 2021 – (ACN Newswire via – A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for […]

New treatment option for schizophrenia – Reagila(R) – listed on PBS this week

– Adults living with schizophrenia will have access to a new treatment option with Reagila(R) (cariprazine) now reimbursed on the Pharmaceutical Benefits Scheme from 1 September, 2021.1 – There continues to be a significant, unmet need in treating schizophrenia. With a complex range of symptoms,2 treatment is not a “one size fits all”.3 This listing […]

Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

TOKYO, Nov 9, 2020 – (JCN Newswire) – Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer’s disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held virtually from November 4 to 7, 2020. […]

Eisai and JD Health Establish JV Company in China to Implement Health Service Platform

TOKYO, Oct 28, 2020 – (JCN Newswire) – Eisai Co., Ltd. and JD Health announced today that Eisai’s Chinese subsidiary Eisai China Inc. and JD Health have established a joint venture company, Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China. In China, due to […]